Amylyx Pharmaceuticals Quarterly Cash Flow Statement
NASDAQ: AMLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
28.14+0.94 (+3.46%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Amylyx Pharmaceuticals free cash flow
In the quarter ended Jun 30, 2026, Amylyx Pharmaceuticals generated -$31.4 million of operating cash flow. That left free cash flow of -$31.4 million.
Summary generated from market data by MetaCap's automated system. Methodology
Amylyx Pharmaceuticals cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -43.42M | -41.28M | -33.00M | -34.39M | -41.44M | -35.91M | -37.55M | -72.70M | -72.70M | -118.79M | 4.73M | 20.89M |
| Net Income growth (YoY) | — | — | — | — | — | — | -893.62% | -447.98% | -429.35% | -7652.00% | — | — |
| Depreciation & Amortization | 43.00K | 98.00K | 108.00K | 120.00K | 141.00K | 156.00K | 160.00K | 221.00K | 208.00K | 315.00K | 301.00K | 302.00K |
| Stock-Based Compensation | 8.32M | 6.12M | 6.39M | 7.08M | 7.35M | 6.83M | 6.74M | 6.80M | 9.57M | 9.92M | 9.53M | 10.18M |
| Change in Working Capital | 4.86M | -6.67M | 1.77M | 1.03M | 4.07M | -9.85M | -27.14M | -14.24M | -12.69M | 2.22M | -807.00K | -34.71M |
| Operating Cash Flow | -31.42M | -36.88M | -27.90M | -30.37M | -25.25M | -39.82M | -59.01M | -41.57M | -66.58M | -489.00K | 13.55M | -5.17M |
| Capital Expenditures | — | — | -86.00K | -24.00K | -17.00K | -11.00K | -20.00K | 19.00K | -89.00K | -67.00K | -356.00K | -357.00K |
| Investing Cash Flow | -149.80M | 36.26M | 29.47M | 5.24M | 22.99M | -43.66M | 64.98M | 38.82M | -28.96M | 819.00K | 20.93M | -108.09M |
| Debt Issued | — | — | -375.00K | 191.11M | 0 | 65.58M | — | — | — | — | — | — |
| Financing Cash Flow | 1.48M | 3.22M | -208.00K | 191.61M | -31.00K | 65.66M | 110.00K | 80.00K | 27.00K | 131.00K | 230.00K | 889.00K |
| Net Change in Cash | -179.81M | 2.49M | 1.48M | 166.63M | -1.68M | -17.62M | 5.56M | -2.44M | -95.55M | 351.00K | 34.94M | -112.50M |
| Free Cash Flow | -31.42M | -36.88M | -27.99M | -30.39M | -25.27M | -39.84M | -59.03M | -41.55M | -66.67M | -556.00K | 13.20M | -5.53M |
This table shows 12 quarterly periods of Amylyx Pharmaceuticals's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AMLX's reporting calendar. What is a cash flow statement?